Humana’s (HUM) Buy Rating Reiterated at Piper Jaffray Companies

Piper Jaffray Companies reissued their buy rating on shares of Humana Inc. (NYSE:HUM) in a research note published on Friday. The brokerage currently has a $246.00 price target on the insurance provider’s stock.

HUM has been the topic of several other research reports. Zacks Investment Research upgraded shares of Humana from a hold rating to a buy rating and set a $256.00 price objective on the stock in a research report on Monday, May 8th. Deutsche Bank AG initiated coverage on shares of Humana in a research report on Wednesday, April 5th. They issued a hold rating and a $216.00 price target on the stock. Argus upgraded shares of Humana from a hold rating to a buy rating and set a $260.00 price target on the stock in a research report on Friday, June 9th. Oppenheimer Holdings, Inc. initiated coverage on shares of Humana in a research report on Thursday, March 30th. They issued an outperform rating and a $236.00 price target on the stock. Finally, Cantor Fitzgerald boosted their price target on shares of Humana from $190.00 to $200.00 and gave the stock a neutral rating in a research report on Wednesday, April 26th. Nine investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Humana presently has an average rating of Buy and a consensus target price of $231.00.

Shares of Humana (NYSE HUM) traded down 1.23% during midday trading on Friday, hitting $234.64. 1,083,820 shares of the stock were exchanged. The company has a market capitalization of $33.86 billion, a P/E ratio of 23.91 and a beta of 0.91. Humana has a 1-year low of $150.00 and a 1-year high of $243.74. The firm has a 50-day moving average of $232.54 and a 200-day moving average of $215.15.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, May 3rd. The insurance provider reported $2.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.55 by $0.20. The firm had revenue of $13.76 billion for the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a net margin of 2.71% and a return on equity of 14.38%. During the same quarter last year, the business posted $1.86 earnings per share. On average, equities analysts expect that Humana will post $11.15 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/07/18/humanas-hum-buy-rating-reiterated-at-piper-jaffray-companies.html.

The business also recently announced a quarterly dividend, which will be paid on Monday, July 31st. Stockholders of record on Friday, June 30th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date is Wednesday, June 28th. Humana’s dividend payout ratio is currently 16.24%.

In other news, CEO Bruce D. Broussard sold 118,231 shares of the business’s stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $225.82, for a total transaction of $26,698,924.42. Following the completion of the sale, the chief executive officer now directly owns 171,170 shares of the company’s stock, valued at $38,653,609.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Timothy S. Huval sold 13,939 shares of the business’s stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $225.86, for a total transaction of $3,148,262.54. Following the sale, the vice president now directly owns 23,639 shares of the company’s stock, valued at $5,339,104.54. The disclosure for this sale can be found here. Insiders have sold 143,241 shares of company stock valued at $32,446,903 over the last three months. Insiders own 0.80% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Guardian Life Insurance Co. of America raised its stake in shares of Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock worth $119,000 after buying an additional 4 shares in the last quarter. Independent Portfolio Consultants Inc. raised its stake in shares of Humana by 22.1% in the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock worth $125,000 after buying an additional 94 shares in the last quarter. Point72 Asia Hong Kong Ltd bought a new stake in shares of Humana during the first quarter worth about $128,000. Westbourne Investment Advisors Inc. bought a new stake in shares of Humana during the second quarter worth about $205,000. Finally, MUFG Americas Holdings Corp bought a new stake in shares of Humana during the first quarter worth about $221,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply